Severe eosinophilic asthma: therapeutic potential of Reslizumab

Abstract

The review discusses the problems associated with the treatment of patients with severe resistant to therapy asthma: prevalence, socio-economic burden, impact on quality of life. The phenotype of bronchial asthma with eosinophilic inflammation, frequency of occurrence, clinical features, and modern approaches to therapy are discussed in detail, including the use of a drug of monoclonal antibodies against interleukin 5-reslizumab.

Keywords

• severe bronchial asthma
• eosinophilic inflammation
• interleukin 5
• reslisumab